OptiNose, Inc., a pioneering biopharmaceutical company headquartered in the United States, focuses on innovative solutions for patients suffering from chronic sinusitis and other nasal conditions. Founded in 2010, OptiNose has made significant strides in the industry, particularly with its unique delivery systems that enhance the efficacy of medications. The company’s flagship products, including the Xhance nasal spray, leverage advanced technology to improve drug absorption and patient compliance. With a commitment to addressing unmet medical needs, OptiNose has established a strong market position, recognised for its contributions to the field of nasal therapeutics. As it continues to expand its operational reach, OptiNose remains dedicated to transforming the treatment landscape for patients worldwide.
How does OptiNose, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
OptiNose, Inc.'s score of 25 is lower than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
OptiNose, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company has not established documented reduction targets or climate pledges, which suggests a lack of formal commitments to reducing its carbon footprint at this time. As a current subsidiary, OptiNose, Inc. may inherit climate-related data and initiatives from its parent organisation, but no specific details have been provided regarding such cascaded information. The absence of emissions data and reduction initiatives places OptiNose, Inc. in a context where it may need to enhance its climate commitments to align with industry standards and expectations. Overall, while OptiNose, Inc. has not disclosed any emissions or reduction targets, the company is positioned to develop a more robust climate strategy in the future.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
OptiNose, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

